DELCATH SYSTEMS, INC. — fact timeline

DELCATH SYSTEMS, INC. reported first quarter ended March 31, 2026 results: revenue $25.0 million, net income Net loss of $1.1 million. Guidance raised.

“Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025”

DELCATH SYSTEMS, INC.: Amended and restated bylaws to update stockholder nomination procedures, officer and chairperson election provisions, indemnification rights, and administrative changes (effective 2025-08-12).

“On August 12, 2025, the Board of Directors (the “Board”) of Delcath Systems, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s Amended and Restated By-Laws (the “Bylaws”), effective immediately.”

DELCATH SYSTEMS, INC. engaged CBIZ CPAs P.C. as its auditor.

“On November 1, 2024, CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum. On March 18, 2025, following the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs was engaged, effective immediately, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2025.”

Marcum LLP resigned as auditor of DELCATH SYSTEMS, INC..

“On March 18, 2025, Delcath Systems, Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the Company’s independent registered accounting firm.”

Bridget Martell was appointed as Class III Director at DELCATH SYSTEMS, INC..

“on May 23, 2024, the Company appointed Bridget Martell, M.A. M.D., as a Class III Director on the Company's Board, commencing on May 23, 2024”

Roger Stoll retired as Director at DELCATH SYSTEMS, INC..

“Following the voting on Proposal 1 (as listed below in Item 5.07) at the Annual Meeting on May 23, 2024, Roger Stoll's previously announced retirement from the Board took effect.”

DELCATH SYSTEMS, INC. reported the first quarter ended March 31, 2024 results: revenue $3.1 million.

“Total revenue for the quarter ended March 31, 2024 was $3.1 million compared to $0.6 million for the same period in the prior year from our sales of HEPZATO in the U.S. and CHEMOSAT in Europe.”

DELCATH SYSTEMS, INC. amended Fifth Amendment with Synerx Pharma, LLC and Mylan Teoranta (effective 2024-04-22).

“On April 22, 2024, Delcath Systems, Inc. (“Delcath”) entered into a Fifth Amendment, effective May 1, 2024 (the “Amendment”), to the License, Supply and Contract Manufacturing Agreement with Synerx Pharma, LLC and Mylan Teoranta, dated October 13, 2010 (as subsequently amended, the “Agreement”), for Delcath’s supply of melphalan hydrochloride (the “Product”).”

DELCATH SYSTEMS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $0.5 million and $2.1 million, respectively. Guidance raised.

“to year-end, on March 19, 2024, the company closed a $7.0 million private placement financing. Total revenue for the quarter and year-ended December 31, 2023, was approximately $0.5 million and $2.1 million, respectively, compared to $0.6 million and $2.7 million for the same periods in the prior year, respectively, from our sales of CHEMOSAT in Europe. Research and”

DELCATH SYSTEMS, INC. entered into Securities Purchase Agreement with certain accredited investors valued at sale of 876,627 shares at $3.72/share and 1,008,102 pre-funded warrants at $3.71/warrant, gross proc (effective 2024-03-14).

“On March 14, 2024, Delcath Systems, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 876,627 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $3.72 per share, and (ii) to certain investors, in lieu of shares of Common Stock, 1,008,102 pre-funded warrants (the “Pre-Funded Warrants”) at a price per Pre-Funded Warrant of $3.71 (the “Warrant Shares” and together with the Shares, the “Securities”).”

John Purpura retired as Chief Operating Officer at DELCATH SYSTEMS, INC..

“As previously reported on February 12, 2024, John Purpura notified the Company of his intent to retire as the Company’s Chief Operating Officer”

Martha S. Rook was appointed as Chief Operating Officer at DELCATH SYSTEMS, INC..

“Effective as of March 18, 2024, Delcath Systems, Inc. (the “Company”) appointed Martha S. Rook, Ph.D., as Chief Operating Officer of the Company.”

Roger Stoll retired as director at DELCATH SYSTEMS, INC..

“on February 9, 2024, Roger Stoll notified the Company of his intent to retire from the board of directors of the Company (the “Board”) and not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).”

John Purpura retired as Chief Operating Officer at DELCATH SYSTEMS, INC..

“On February 12, 2024, John Purpura notified Delcath Systems, Inc. (the “Company”) of his intent to retire as the Company’s Chief Operating Officer.”

DELCATH SYSTEMS, INC. reported third quarter ended September 30, 2023 results: revenue approximately $0.4 million.

“Total revenue for the three months ended September 30, 2023, was approximately $0.4 million, compared to $0.9 million for the prior year period”

DELCATH SYSTEMS, INC. reported the second quarter ended June 30, 2023 results: revenue approximately $0.5 million.

“Total revenue for the three months ended June 30, 2023, was approximately $0.5 million, compared to $0.8 million for the prior year period, from our sales of CHEMOSAT in Europe.”

DELCATH SYSTEMS, INC.: Increase authorized common shares from 40,000,000 to 80,000,000 shares (effective 2023-06-12).

“At the Annual Meeting, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of Common Stock from 40,000,000 shares to 80,000,000 shares. The increase in the authorized number of shares of the Common Stock was effected pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 12, 2023 and was effective as of such date.”

DELCATH SYSTEMS, INC. shareholders approved Non-binding advisory vote on preferred frequency of holding future advisory votes on executive compensation at the 2023-06-12 meeting.

“Proposal 7. Stockholders approved a non-binding advisory vote on the preferred frequency of holding future advisory votes on compensation of the Company’s named executive officers.”

DELCATH SYSTEMS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-12 meeting.

“Proposal 6. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers.”

DELCATH SYSTEMS, INC. shareholders approved Ratification of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-12 meeting.

“Proposal 5. Stockholders ratified the selection by the Audit Committee of the Board of Marcum, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023.”

DELCATH SYSTEMS, INC. shareholders approved Approval of potential issuance in excess of 19.99% of outstanding Common Stock upon conversion of Series F Convertible Preferred Stock under Nasdaq Listing Rule 5635 at the 2023-06-12 meeting.

“Proposal 4. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding Common Stock upon the conversion of the Company’s Series F-1 Convertible Preferred Stock, par value $0.01 per share, Series F-2 Convertible Preferred Stock, par value $0.01 per share, Series F-3 Convertible Preferred Stock, par value $0.01 per share and Series F-4 Convertible Preferred Stock, par value $0.01 per share (collectively, the “Series F Preferred Stock”) at less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Voting Preferred Stock governing the Series F Preferred Stock.”

DELCATH SYSTEMS, INC. shareholders approved Amendment to 2020 Omnibus Equity Incentive Plan to increase shares available by 2,650,000 at the 2023-06-12 meeting.

“Proposal 3. Stockholders approved the amendment to the Company’s 2020 Omnibus Equity Incentive Plan to increase by 2,650,000 the number of shares of Common Stock available under thereunder.”

DELCATH SYSTEMS, INC. shareholders approved Amendment to increase authorized Common Stock from 40,000,000 to 80,000,000 shares at the 2023-06-12 meeting.

“Proposal 2. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its Common Stock authorized for issuance from 40,000,000 shares to 80,000,000 shares.”

DELCATH SYSTEMS, INC. shareholders approved Election of Class II Directors at the 2023-06-12 meeting.

“Proposal 1. Stockholders elected each of the following nominees to serve as Class II directors on the Company’s Board of Directors (the “Board”) until the Company’s 2026 Annual Meeting of Stockholders or until his successor has been duly elected and qualified.”

Sandra Pennell was appointed as Senior Vice President of Finance and principal financial and accounting officer at DELCATH SYSTEMS, INC..

“On June 1, 2023, and effective as of the date thereof, Delcath Systems, Inc. (the “Company”) appointed Sandra Pennell as Senior Vice President of Finance and principal financial and accounting officer of the Company.”

DELCATH SYSTEMS, INC. reported preliminary financial results for first quarter ended March 31, 2023.

“Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023.”

DELCATH SYSTEMS, INC.: Filed Certificate of Designation for Series F Preferred Stock, establishing rights and preferences of four new series of preferred stock (effective 2023-03-28).

“Pursuant to the terms of the Preferred Purchase Agreement, on March 28, 2023, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 24,900 shares of its authorized and unissued preferred stock as Series F-1 Preferred Stock, 24,900 shares as Series F-2 Preferred Stock, 34,860 shares as Series F-3 Convertible Preferred Stock and 24,900 shares as Series F-4 Convertible Preferred Stock”

DELCATH SYSTEMS, INC. entered into Common Purchase Agreement with Gerard Michel valued at approximately $100,000 (effective 2023-03-27).

“On March 27, 2023, the Company entered into a securities purchase agreement (the “ Common Purchase Agreement ”) with the Company’s Chief Executive Officer, Gerard Michel (the “ Common Investor ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Common Offering ”), (i) 19,646 shares of Common Stock (the “ Shares ”), (ii) tranche A warrants (“ Common Tranche A Warrant”) to acquire Common Stock, tranche B warrants (the “ Common Tranche B Warrant ”, together with the Common Tranche A Warrant, the “ Common Warrants ”) to acquire shares of Common Stock for an approximate aggregate offering price of $100,000.”

DELCATH SYSTEMS, INC. entered into Preferred Purchase Agreement with certain accredited investors valued at approximately $24.9 million (effective 2023-03-27).

“On March 27, 2023, Delcath Systems, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Preferred Purchase Agreement ”) with certain accredited investors (the “ Preferred Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Preferred Offering ”), (i) 24,900 shares of Series F-1 Convertible Preferred Stock, par value $0.01 per share (the “ Series F-1 Preferred Stock ”), (ii) tranche A warrants (the “ Preferred Tranche A Warrant ”) to acquire shares of Series F-3 Preferred Stock, par value $0.01 per share (the “ Series F-3 Preferred Stock ”) and (iii) tranche B warrants (the “ Preferred Tranche B Warrant ,” together with the Preferred Tranche A Warrant, the “ Preferred Warrants ”) to acquire shares of Series F-4 Preferred Stock, par value $0.01 per share (the “ Series F-4 Preferred Stock ” and together with the Series F-3 Preferred Stock, the “ Preferred Warrant Shares ”) for an aggregate offering price of $24.9 millio”

DELCATH SYSTEMS, INC. reported financial results for the fiscal quarter and year ended December 31, 2022.

“On March 27, 2023, Delcath Systems, Inc. (the “Company”) issued a press release, furnished as Exhibit 99.1 and incorporated in this Item 2.02 by reference, announcing its financial results for the fiscal quarter and year ended December 31, 2022.”

DELCATH SYSTEMS, INC. entered into Securities Purchase Agreement with certain accredited investors valued at gross proceeds from the Private Placement of approximately $6.2 million (effective 2022-12-07).

“On December 7, 2022, Delcath Systems, Inc. ( the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)”

DELCATH SYSTEMS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“October 26, 2022, Delcath Systems, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the requirement to maintain a minimum market value of listed securities of $35 million, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”) , because the market value of the Company’s common stock (the “Common Stock”) was below $35 million for 30 consecutive business days. The market value of the Common Stock is calculated based upon the most re”

Christine Padula resigned as interim principal accounting officer at DELCATH SYSTEMS, INC..

“On October 20, 2021, Christine Padula informed Delcath Systems, Inc. (the “Company”) of her intention to resign as interim principal accounting officer of the Company, effective November 15, 2021, to pursue a new opportunity.”